Essential Pharma Completes refinancing and two significant M&A Transactions
Geneva, December 21st, 2021
Gyrus Capital backed Essential Pharma has completed a refinancing providing capital for Essential Pharma to continue its organic and inorganic growth strategy
Essential Pharma has expanded its global product portfolio through two M&A transactions completed in December 2021
Disposal of Essential Pharma Liquids Limited to Rosemont Pharmaceuticals and acquisition of Yorkdale Pharma
Essential Pharma has divested its 14-product portfolio, Essential Pharma Liquids Limited to Rosemont Pharmaceuticals Limited. In conjunction with this divestiture, Essential Pharma also acquired Yorkdale Pharma Limited from Rosemont Pharmaceutical, adding five products to the Essential Pharma portfolio.
Acquisition of two products from Novartis
Essential Pharma significantly expands its global portfolio with product acquisitions for ocular and postpartum therapies from Novartis. Representing the worldwide rights (excluding US and India), these products are sold in over 50 countries worldwide, and their acquisition brings significant expansion to Essential Pharma’s portfolio as the company executes on its global growth ambitions.
Essential Pharma is an international speciality pharmaceutical company dedicated to maintaining access to medicines for patients across multiple therapeutic areas. The company has been an important and valued partner to healthcare providers for over 20 years by giving patients access to medicines that would otherwise would not be available.
Gyrus Capital is a European private equity firm focused on transformational investments in the healthcare and sustainability sectors. Based in Geneva, Switzerland, Gyrus leverages its sector focus to source, build and transform businesses in the healthcare and sustainability industries that have long-term, sustainable growth potential. Gyrus has a focus on complex transactions, with particular focus on corporate carve outs in the €50 million to €500 million range.
To learn more, please visit www.gyruscapital.com
